Clinical Trial

Serial Blood Count Study

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of the Serial Blood Count Study is to determine the utility of home monitoring of white blood cell (WBC) and absolute neutrophil counts (ANC) to diagnose cyclic neutropenia and distinguish between cyclic and severe congenital neutropenia (SCN). A new home monitoring device called Athelas One was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC). The investigators believe this device provides a unique and extremely valuable opportunity to for diagnosis of these diseases.
Trial Details
NCT Number NCT07066085
Lead Sponsor University of Washington
Conditions Cyclic Neutropenia, Congenital Neutropenia, Neutropenia
Enrollment 20 participants
Start Date 2024-10-17
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-15